AU2022302841A1 - Method for preparing intermediate for synthesis of xanthine oxidase inhibitor - Google Patents
Method for preparing intermediate for synthesis of xanthine oxidase inhibitor Download PDFInfo
- Publication number
- AU2022302841A1 AU2022302841A1 AU2022302841A AU2022302841A AU2022302841A1 AU 2022302841 A1 AU2022302841 A1 AU 2022302841A1 AU 2022302841 A AU2022302841 A AU 2022302841A AU 2022302841 A AU2022302841 A AU 2022302841A AU 2022302841 A1 AU2022302841 A1 AU 2022302841A1
- Authority
- AU
- Australia
- Prior art keywords
- cyano
- hydrogen
- isopropyl
- alkyl
- indole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 62
- 230000015572 biosynthetic process Effects 0.000 title abstract description 6
- 238000003786 synthesis reaction Methods 0.000 title abstract description 6
- 239000003064 xanthine oxidase inhibitor Substances 0.000 title abstract description 6
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 title abstract description 5
- 239000003446 ligand Substances 0.000 claims abstract description 26
- 150000001875 compounds Chemical class 0.000 claims abstract description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 54
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 47
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 38
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 37
- 238000002425 crystallisation Methods 0.000 claims description 32
- 230000008025 crystallization Effects 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 32
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 28
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 28
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 21
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 20
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 150000002431 hydrogen Chemical group 0.000 claims description 17
- 239000010949 copper Substances 0.000 claims description 15
- 239000003054 catalyst Substances 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical group 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 229910052802 copper Inorganic materials 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910021591 Copper(I) chloride Inorganic materials 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 5
- 239000012296 anti-solvent Substances 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 239000004215 Carbon black (E152) Substances 0.000 claims description 4
- 229910021589 Copper(I) bromide Inorganic materials 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 4
- 150000002430 hydrocarbons Chemical class 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 4
- 229910000404 tripotassium phosphate Inorganic materials 0.000 claims description 4
- 235000019798 tripotassium phosphate Nutrition 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 3
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000001508 potassium citrate Substances 0.000 claims description 2
- 229960002635 potassium citrate Drugs 0.000 claims description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 2
- 235000011082 potassium citrates Nutrition 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 2
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 claims 2
- 229960005235 piperonyl butoxide Drugs 0.000 claims 2
- FMKOJHQHASLBPH-OUBTZVSYSA-N 2-iodopropane Chemical group CC([13CH3])I FMKOJHQHASLBPH-OUBTZVSYSA-N 0.000 claims 1
- 235000019270 ammonium chloride Nutrition 0.000 claims 1
- SGFKGWBZTJDCEU-UHFFFAOYSA-L dipotassium;n,n-dimethylformamide;carbonate Chemical compound [K+].[K+].[O-]C([O-])=O.CN(C)C=O SGFKGWBZTJDCEU-UHFFFAOYSA-L 0.000 claims 1
- 235000015320 potassium carbonate Nutrition 0.000 claims 1
- 235000011181 potassium carbonates Nutrition 0.000 claims 1
- BHAROVLESINHSM-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1.CC1=CC=CC=C1 BHAROVLESINHSM-UHFFFAOYSA-N 0.000 claims 1
- 239000007858 starting material Substances 0.000 abstract description 6
- 238000000605 extraction Methods 0.000 abstract description 5
- 238000000746 purification Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 83
- 239000010410 layer Substances 0.000 description 47
- 238000010626 work up procedure Methods 0.000 description 33
- 239000012535 impurity Substances 0.000 description 30
- PIVMHSHSPPOYTK-UHFFFAOYSA-N BrC1=CC=C2N(C(C)C)C=C(C#N)C2=C1 Chemical compound BrC1=CC=C2N(C(C)C)C=C(C#N)C2=C1 PIVMHSHSPPOYTK-UHFFFAOYSA-N 0.000 description 28
- 238000000926 separation method Methods 0.000 description 26
- 238000010992 reflux Methods 0.000 description 24
- ZPUQCVKBNRGSAP-UHFFFAOYSA-N 5-bromo-1h-indole-3-carbonitrile Chemical compound BrC1=CC=C2NC=C(C#N)C2=C1 ZPUQCVKBNRGSAP-UHFFFAOYSA-N 0.000 description 20
- 238000004128 high performance liquid chromatography Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- -1 5-bromo-3-cyano--isopropyl-indole Chemical compound 0.000 description 14
- 238000012216 screening Methods 0.000 description 14
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- XSRLHGSAMGVDJU-UHFFFAOYSA-N 2-propan-2-yl-1h-indole Chemical compound C1=CC=C2NC(C(C)C)=CC2=C1 XSRLHGSAMGVDJU-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 8
- 239000007810 chemical reaction solvent Substances 0.000 description 8
- JLQQRYOWGCIMMZ-UHFFFAOYSA-N 1-(3-cyano-1-propan-2-ylindol-5-yl)pyrazole-4-carboxylic acid Chemical compound C=1C=C2N(C(C)C)C=C(C#N)C2=CC=1N1C=C(C(O)=O)C=N1 JLQQRYOWGCIMMZ-UHFFFAOYSA-N 0.000 description 7
- 238000004821 distillation Methods 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 230000035484 reaction time Effects 0.000 description 7
- 229910017917 NH4 Cl Inorganic materials 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 5
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 5
- OVMPROUSMUVTJY-UHFFFAOYSA-N ethyl 1-(3-cyano-1-propan-2-ylindol-5-yl)pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=CC=C(N(C=C2C#N)C(C)C)C2=C1 OVMPROUSMUVTJY-UHFFFAOYSA-N 0.000 description 5
- KACZQOKEFKFNDB-UHFFFAOYSA-N ethyl 1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1 KACZQOKEFKFNDB-UHFFFAOYSA-N 0.000 description 5
- 125000004494 ethyl ester group Chemical group 0.000 description 5
- 150000002475 indoles Chemical class 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000002910 solid waste Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229940116269 uric acid Drugs 0.000 description 5
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229940075420 xanthine Drugs 0.000 description 4
- DIANQUVNTSJNPS-UHFFFAOYSA-N 1-propan-2-ylindole-3-carbonitrile Chemical compound C1=CC=C2N(C(C)C)C=C(C#N)C2=C1 DIANQUVNTSJNPS-UHFFFAOYSA-N 0.000 description 3
- CHIFTAQVXHNVRW-UHFFFAOYSA-N 1h-indole-3-carbonitrile Chemical compound C1=CC=C2C(C#N)=CNC2=C1 CHIFTAQVXHNVRW-UHFFFAOYSA-N 0.000 description 3
- VXWVFZFZYXOBTA-UHFFFAOYSA-N 5-bromo-1h-indole Chemical compound BrC1=CC=C2NC=CC2=C1 VXWVFZFZYXOBTA-UHFFFAOYSA-N 0.000 description 3
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- IMBBXSASDSZJSX-UHFFFAOYSA-N 4-Carboxypyrazole Chemical compound OC(=O)C=1C=NNC=1 IMBBXSASDSZJSX-UHFFFAOYSA-N 0.000 description 2
- HKFRSBDQHJWUDN-UHFFFAOYSA-N Brn1cc(C#N)c2ccccc12 Chemical compound Brn1cc(C#N)c2ccccc12 HKFRSBDQHJWUDN-UHFFFAOYSA-N 0.000 description 2
- 238000012369 In process control Methods 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000010965 in-process control Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- PUPKPAZSFZOLOR-UHFFFAOYSA-N n,n-dimethylformamide;toluene Chemical compound CN(C)C=O.CC1=CC=CC=C1 PUPKPAZSFZOLOR-UHFFFAOYSA-N 0.000 description 2
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000012421 spiking Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- JDFIJVJKRTZYCK-UHFFFAOYSA-N 1-propan-2-ylindole Chemical compound C1=CC=C2N(C(C)C)C=CC2=C1 JDFIJVJKRTZYCK-UHFFFAOYSA-N 0.000 description 1
- ZPRQXVPYQGBZON-UHFFFAOYSA-N 2-bromo-1h-indole Chemical compound C1=CC=C2NC(Br)=CC2=C1 ZPRQXVPYQGBZON-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 101710178035 Chorismate synthase 2 Proteins 0.000 description 1
- 101710152694 Cysteine synthase 2 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229940087098 Oxidase inhibitor Drugs 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000006887 Ullmann reaction Methods 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- DMMLYDCVMZEUMT-UHFFFAOYSA-N benzo[h]cinnoline Chemical compound C1=NN=C2C3=CC=CC=C3C=CC2=C1 DMMLYDCVMZEUMT-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- YMHQVDAATAEZLO-UHFFFAOYSA-N cyclohexane-1,1-diamine Chemical compound NC1(N)CCCCC1 YMHQVDAATAEZLO-UHFFFAOYSA-N 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- PAUPUUZSICTYGB-UHFFFAOYSA-N indole-1-carbonitrile Chemical compound C1=CC=C2N(C#N)C=CC2=C1 PAUPUUZSICTYGB-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- CGRKYEALWSRNJS-UHFFFAOYSA-N sodium;2-methylbutan-2-olate Chemical compound [Na+].CCC(C)(C)[O-] CGRKYEALWSRNJS-UHFFFAOYSA-N 0.000 description 1
- 238000009270 solid waste treatment Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Indole Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a method for preparing an intermediate for synthesis of a xanthine oxidase inhibitor and, more specifically, to a method for preparing compounds of chemical formulas 2 and 4 by using low-priced starting materials and ligands and employing chelating extraction and purification techniques.
Description
The present invention relates to methods of preparing intermediates for
synthesizing xanthine oxidase inhibitor. More specifically, the present invention relates
to methods for preparing compounds of the following Formula 2 and Formula 4 by using
inexpensive starting materials and ligands, and a purification technique utilizing chelating
extraction:
[Formula 2] R1
X K\R2 R3
[Formula 4] R4
R5 R1 NN
R3
wherein, X is F, Cl, Br or I;
R1 is hydrogen or CN;
R2 is hydrogen, halogen, C1 -C 7 alkyl, C1 -C 7 alkoxy-C1-C7 alkyl or phenyl;
R3 is hydrogen; C1 -C 7 alkyl unsubstituted or substituted by one or more
substituents selected from halogen, C3-C 7 cycloalkyl and O-R6; C3-C 7 cycloalkyl; or
w R7 , wherein R6 is C 1-C 4 alkyl, W is 0 or S, R7 is hydrogen or C1 -C 4 alkyl,
and n is an integer of 0 to 3;
R4 is hydrogen, halogen or C1 -C 7 alkyl; and
R5 is -C(O)OR8, wherein R8 is hydrogen, C1 -C 7 alkyl or C3-C 7 cycloalkyl.
Xanthine oxidase is known as an enzyme which converts hypoxanthine to
xanthine and further converts thus-formed xanthine to uric acid. Although most
mammals have uricase, humans and chimpanzees do not, thereby uric acid is known to
be the final product of purine metabolism (S. P. Bruce, Ann. Pharm., 2006, 40, 2187
2194). Sustained elevation of blood concentration of uric acid causes various diseases,
representatively including gout.
As described above, gout is caused by an elevated level of uric acid in the body,
indicating the condition in which uric acid crystals accumulated in cartilage, ligament and
surrounding tissue induce severe inflammation and pain. Gout is a kind of inflammatory
articular disease, and its incidence rate has steadily increased during past 40 years (N. L.
Edwards, Arthritis & Rheumatism, 2008, 58, 2587-2590).
Accordingly, various studies have been conducted to develop new xanthine
oxidase inhibitors, and Korean Patent Application Publication No. 10-2011-0037883
discloses a novel compound of the following formula, which is effective as a xanthine
oxidase inhibitor:
0 A D
In Korean Patent Application Publication No. 10-2011-0037883 disclosing a
conventional preparation step of 5-bromo-3-cyano--isopropyl-indole-which is an
intermediate of the xanthine oxidase inhibitor, CsCO3-which is inconvenient to use due
to its low economic effectiveness and high density-was used, so that it was necessary to
secure a substitute for it. In addition, since there is no established purification method,
the organic layer obtained after the reaction and work-up process was concentrated and
the next reaction was carried out immediately. At this time, there was a problem in that
-bromo-3-cyano--isopropyl-indole included in the reaction mixture because it was not
purified acts as a causative material for generating impurity in the next reaction, adversely
affecting product quality.
Furthermore, the conventional preparation step for 1-(3-cyano--isopropyl
indol-5-yl)pyrazole-4-carboxylic acid ethyl ester has a very long reaction time of 35 to
48 hours, and the starting material, 5-bromo-3-cyano--isopropyl-indole, remains and
various impurities are generated. As a result, such materials can affect raw material
medicine, so that it was necessary to improve the quality and yield. In addition, after
completion of the reaction for 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic
acid ethyl ester, Na2SO 4 and silica gel were put into the reactor and then the adsorption
process was carried out to remove Cu-complex and in-organic by-products in the work
up process. At this time, there is an issue of cleaning the manufacturing equipment. In
addition, because filtration and washing to remove adsorbents and solid complexes lengthened the process time, and solid waste treatment was difficult, it is necessary to develop an effective purification method.
[Prior Document]
Patent Document: Korean Patent Application Publication No. 10-2011-0037883
Accordingly, the technical problem of the present invention is the provision of
novel methods for preparing compounds of Formula 2 and Formula 4, which are key
intermediates in the synthesis of xanthine oxidase inhibitors, at a lower cost, effectively
reducing residual impurity, shortening reaction time, improving yield and eliminating the
possibility of generating solid waste:
[Formula 2]
R1
X K\R2
R3
[Formula 4]
R4
R5 RI Nj R2 NN
R3
wherein X, RI, R2, R3, R4 and R5 are the same as defined herein.
To solve the above technical problem, there is provided a method for preparing a
compound of the following Formula 2, comprising:
i) a step of reacting a compound of Formula 1 and X-R3 with a base comprising
KOH in an organic solvent; and
ii) a step of crystallizing a product obtained in step (i) by using alcohol and an
anti-solvent comprising hydrocarbon having 5 to 8 carbon atoms:
[Formula 1]
R1
X1 N
[Formula 2]
R1
X K\R2 R3
wherein,
X is F, Cl, Br or I;
R1 is hydrogen or CN;
R2 is hydrogen, halogen, CI-C7 alkyl, C-C7 alkoxy-Ci-C7 alkyl or phenyl; and
R3 is hydrogen; C1 -C 7 alkyl unsubstituted or substituted by one or more
substituents selected from halogen, C 3 -C 7 cycloalkyl and O-R6; C 3 -C 7 cycloalkyl; or w
R7 , wherein R6 is C 1-C 4 alkyl, W is 0 or S, R7 is hydrogen or C 1 -C 4 alkyl,
and n is an integer of 0 to 3.
According to one embodiment of the present invention, X-R3 may be 2
iodopropane, but is not limited thereto.
According to one embodiment of the present invention, the organic solvent may
be acetone, but is not limited thereto.
According to one embodiment of the present invention, the alcohol may be one
or more selected from the group consisting of methanol, ethanol, propanol, isopropanol
and butanol, but is not limited thereto.
According to one embodiment of the present invention, the hydrocarbon having
to 8 carbon atoms may be selected from the group consisting of hexane, heptane and a
mixture thereof, but is not limited thereto.
According to one embodiment of the present invention, RI may be CN, R2 may
be hydrogen, and R3 may be isopropyl, but is not limited thereto.
According to another aspect of the present invention, there is provided a method
for preparing a compound of the following Formula 4, comprising:
a step of carrying out a C-N coupling reaction of a compound of Formula 2 and
a compound of Formula 3 with a copper catalyst, a base and a ligand comprising N,N
dimethylethylenediamine in an organic solvent:
[Formula 2]
R1 X
R3
[Formula 3]
R4 N NH
[Formula 4]
R4
R5 I R1 N
R3
wherein,
X is F, Cl, Br or I;
RI is hydrogen or CN;
R2 is hydrogen, halogen, C1 -C 7 alkyl, C1 -C 7 alkoxy-C1-C7 alkyl or phenyl;
R3 is hydrogen; C1 -C 7 alkyl unsubstituted or substituted by one or more
substituents selected from halogen, C 3 -C 7 cycloalkyl and O-R6; C 3 -C 7 cycloalkyl; or
W R7 , wherein R6 is CI-C4 alkyl, W is 0 or S, R7 is hydrogen or C1-C4 alkyl,
and n is an integer of 0 to 3;
R4 is hydrogen, halogen or C1 -C 7 alkyl; and
-7-.
R5 is -C(O)OR8, wherein R8 is hydrogen, C1 -C 7 alkyl or C3-C 7 cycloalkyl.
According to one embodiment of the present invention, the organic solvent may
be one or more selected from the group consisting of xylene, toluene, dimethylformamide
(DMF) and dimethyl sulfoxide (DMSO), but is not limited thereto.
According to one embodiment of the present invention, the copper catalyst may
be one or more selected from the group consisting of Cu, Cu(OAc)2, Cu, Cu20 and CuO,
but is not limited thereto.
According to one embodiment of the present invention, the base may be one or
more selected from the group consisting of potassium carbonate, cesium carbonate,
potassium phosphate tribasic, triethylamine and sodium tert-butoxide, but is not limited
thereto.
According to one embodiment of the present invention, the method for preparing
a compound of Formula 4 may further comprise a step of purifying the compound of
Formula 4 by using:
one or more chelating agents selected from the group consisting of EDTA, citric
acid, potassium citrate and sodium citrate; and
one or more ligand reagents selected from the group consisting of ammonium
chloride and aqueous ammonia, but is not limited thereto.
According to one embodiment of the present invention, RI may be CN, R2 may
be hydrogen, R3 may be isopropyl, R4 may be hydrogen, and R5 may be ethoxycarbonyl
(-C(O)OEt), but is not limited thereto.
The preparation method according to the present invention can secure economic effectiveness and effectively reduce residual impurity by replacing expensive Cs2CO3 with remarkably inexpensive KOH in the preparation of the compound of Formula 2. In addition, the preparation method according to the present invention dramatically shortens the reaction time in the preparation of the compound of Formula 4, and at the same time dramatically improves the yield compared to the conventional method and significantly reduces the possibility of generating solid waste, thereby making it easier to scale up.
Figure 1 is a comparison of HPLC peak areas of residual 5-bromo-3-cyano-1H
indole before and after crystallization of5-bromo-3-cyano-1-isopropyl-indole. (GD40: 5
bromo-3-cyano-1H-indole, GD60: 5-bromo-3-cyano-1-isopropyl-indole)
Figure 2 represents the structures of the ligands subjected to the reaction of 1-(3
cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester.
Figure 3 represents the HPLC conversion ratio (%) of 5-bromo-3-cyano-1
isopropyl-indole into 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acidethyl
ester.
Figure 4 represents the HPLC conversion ratio (%) of 5-bromo-3-cyano-1
isopropyl-indole into 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acidethyl
ester.
Figure 5 represents the HPLC conversion ratio (%) of 5-bromo-3-cyano-1
isopropyl-indole into 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl
ester.
Hereinafter, the present invention is explained in more detail with the following
-9Q- examples. However, it must be understood that the protection scope of the present invention is not limited to the examples.
Example 1: Results of 5-bromo-3-cyano-1-isopropyl-indole reaction test
Example 1.1: Base screening of 5-bromo-3-cyano-1-isopropyl-indole
Cs2CO3, which is a raw material used for the synthesis of 5-bromo-3-cyano-1
isopropyl-indole in the previously known process, is quite expensive, and 1.7 equivalents
thereof in respect to 5-bromo-3-cyano-1H-indole were added to the reaction and
accounted for about 1% of the cost of raw materials. In addition, due to the high density
of Cs2CO3 (density: 4.07 g/cm 3 ), the agitation speed operation range was increased for
smooth stirring during the reaction. In order to solve such problems, 5-bromoindole was
first selected as an indole source and screening for various bases was carried out in the
following Reaction Scheme 1 (Table 1).
[Reaction Scheme 1]
Br 2-lodopropane Br
/~ N Solvent, Base N H Temperature Time 5-Bromo Indole Isopropylated Product
[Table 1] Isopropylation screening experiment of 5-bromoindole
Result (HPLC %ratio) Base Solvent Temp. Time Run 16 min 18 min 20 min 23 min (equiv) (fold) (°C) (h) (SM) (rt)
Example C23 52.5 8.6 2.1 36.6 1-1-1 (1.7) DMF 25 2.5 Example K2CO 3 (10) 96.2 3.6 0.2 1-1-2 (1.7)
Example STP 41.3 - 2.5 56.2 1-1-3 (1.7) Example NaGMe 50.2 - 1.3 48.5 1-1-4 (1.7) Example KOH 15.4 - 2.0 82.6 1-1-5 (1.7) Example CS2CO3 DMF 6.0 61.8 - 2.5 1-1-6 (1.7) (6) Example CS 2 CO3 59.2 - 2.3 38.5 1-1-7 (1.7) Example K23 74.0 0.7 1.1 24.1 1-1-8 (1.7) Example STP DMF 90 5.0 37.6 - 2.4 59.9 1-1-9 (1.7) (10) Example NaGMe 16.6 - 1.6 81.8 1-1-10 (1.7) Example KOH 16.0 - 1.9 81.9 1-1-11 (1.7) Example KOH 13.7 - 1.65 84.1 1-1-12 (2.0) Example KOH 8.3 - 1.7 90.0 1-1-13 (2.0) 35 3.5 Example KOH 14.0 0.8 1.1 83.8 1-1-14 (2.4) Example KOH DMF 1.45 1.1 0.6 96.9 1-1-15 (2.4) (10) Example NaGMe 53.1 1.9 2.1 42.9 1-1-16 (2.0) Example NaOMe 90 6.0 63.0 2.7 1.7 32.6 1-1-17 (2.0) Example NaGMe 54.0 - 2.2 43.8 1-1-18 (2.4)
STP: sodium tert-pentoxide
1.7 Equivalents of 2-iodopropane and DMF as the reaction solvent were selected,
and a suitable base in terms of the ratio of conversion to the alkylated product was predicted while changing the reaction temperature and reaction time. In Examples 1-1-1 to 1-1-5, KOH showed the highest conversion ratio. In the case of Examples 1-1-7 to
1-1-11, after raising the reaction temperature to 90°C, the reaction was performed. As
a result, the conversion ratio tendency of K2 C3 < Cs2CO3 < STP < NaOMe : KOH
can be known.
In Examples 1-1-12 to 1-1-18, the reaction temperature and equivalent were
changed in order to compare KOH and NaOMe. As a result, when KOH was used as a
base, the most desirable results were obtained. Based on the experiment in Table 1, an
isopropylation reaction was carried out in the following Reaction Scheme 2 using 5
bromo-3-cyano-H-indole in which CN group is substituted at the C3 position of 5
bromoindole (Table 2).
[Reaction Scheme 2]
CN CN Br 2-lodopropane Br
N Solvent, Base N H Temperature Time GD40 GD60
[Table 2] 5-Bromo-3-cyano-1H-indole isopropylation screening experiment I
2-lodo Result (HPLC % ratio) Base Solvent Temp. Time Run propane 10 14 min 16 18 min (uv)(equiv) (equiv) (fold) (°C) (h) mm min GD)mm (GD40) min (DO (GD60) Example 1.7 Cs2CO3 Acetone 60 3.0 1.11 N/D 2.17 95.06 1-2-1 (1.7) (5) Example KOH 1.7 r.t 5.0 0.83 18.10 2.55 78.42 1-2-2 (1.7) DMF Example 2.2 KOH (7) r.t 4.0 0.93 11.68 2.86 84.37 1-2-3 (1.7)
Example KOH 1.7 154 7.0 0.43 7.40 1.78 89.75 1-2-4 (1.7) Example KOH Acetone 1.7 60 4.6 1.24 N/D 1.89 95.45 1-2-5 (1.7) (7) GD40:5-Bromo-3-cyano-1H-indole GD60:5-Bromo-3-cyano-1-isopropyl-indole
Through Example 1-2-1, it was confirmed that after completion of the reaction
under the reaction conditions of 5-bromo-3-cyano-1-isopropyl-indole, 5-bromo-3-cyano
1H-indole does not remain. In Examples 1-2-2 to 1-2-4, Cs2CO3 was replaced with
KOH, and the reaction was carried out in a DMF solvent. As a result of changing the
reaction temperature, and the equivalents of 2-iodopropane and KOH, the reaction
proceeded well, but it was confirmed that 0.43 - 0.93% of the starting material (5-bromo
3-cyano-1H-indole) remained. In Example 1-2-5, KOH was used as the base, the
reaction solvent was changed from DMF to acetone, and the reaction was carried out
under reflux conditions. As a result, it was confirmed that results are similar to those
using conventional Cs2CO3. Therefore, it was found that Cs2CO3 can be changed to
KOH. Additional experiments were conducted to verify the results of Tables 1 and 2
above. It was necessary to check the change in the content of de-isopropylated impurity
generated during the work-up process after completion of the reaction and the actual
isolation yield as well as the ratio of conversion to isopropylated product in the 5-bromo
3-cyano-1-isopropyl-indole reaction. The contents of the reactions using 7 types of base
and acetone as a reaction solvent under reflux condition in the following Reaction Scheme
3 are summarized (Table 3).
[Reaction Scheme 3]
CN CN Br 2-lodopropane (1.7 equiv) Br
/ N Acetone (5 fold) N H Base (1.7 equiv) Reflux GD40 GD60
[Table 3] 5-Bromo-3-cyano-1H-indole isopropylation screening experiment II
De-isopropylated Impurity (5-bromo- Gross Net
Run Base Time 3-cyano-1H-indole) HPLC ratio (%) (equiv) (h) Before After After w/up w/up concentration Example Cs2CO3 2.0 0.03 0.16 0.15 96.89 98.65 1-3-1 Example iOH 12.0 15.37 12.76 24.80 99.83 88.41 1-3-2 Example Ca(OH) 2 24.0 99.45 N/A N/A N/A N/A 1-3-3 Example NaOH 5.0 0.83 0.95 0.01 84.54 85.04 1-3-4 Example KOH 3.0 0.12 0.29 0.01 100.97 98.76 1-3-5 Example K2 C0 3 6.0 65.03 N/A N/A N/A N/A 1-3-6 Example NaOAc 6.0 N/A N/A N/A N/A N/A 1-3-7
Example 1-3-1 is an experiment using CS2CO 3 which was used in the
isopropylation reaction, and it was confirmed that de-isopropylated impurity increased
from 0.03% to 0.16% when work up and concentration were performed after completion
of the reaction. In the case of Example 1-3-2, LiOH was used as a base, and after work
up, the organic layer was separated and concentrated, and the sample was analyzed before
proceeding with the crystallization process. As a result, it was confirmed that the de
isopropylated impurity increased from 12.76% to 24.80%. In the experiments using
NaOH and KOH in Examples 1-3-4 and 1-3-5, the tendency of de-isopropylated impurity
to increase during the work up process was also confirmed. Considering the amount of
tarr production in the middle layer generated during work up, reaction time, isolation
yield and base price, it was concluded that it is preferable to use KOH rather than Cs2CO3.
Example 2: Test results of 5-bromo-3-cyano-1-isopropyl-indole crystallization
Example 2.1: Process study for 5-bromo-3-cyano-1-isopropyl-indole
crystallization
As described in Example 1 above, when the de-isopropylated impurity remains
in the process of 5-bromo-3-cyano-1-isopropyl-indole, indole dimer impurity was
generated in the C-N coupling reaction of 1-(3-cyano--isopropyl-indole-5-yl)pyrazole
4-carboxylic acid ethyl ester, but it was not easy to remove in the later manufacturing
process.
[Reaction Scheme 4] Generation of indole dimer impurity by de-isopropylated impurity
CN CN CN Br 2-lodopropane Br Br
N Acetone, Cs2CO3 N - N H Reflux H
GD40 _ GDGO N-dealkylated Impurity
Et0 2C
N N Et0 2C N N N. _
EtO 2C N CN + N
Nm Indoledimer Impurity GD65
GD40: 5-Bromo-3-cyano-1H-indole GD60: 5-Bromo-3-cyano-1-isopropyl-indole GD65: 1-(3-Cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester
Specifically, although de-isopropylated impurity was hardly generated during the
reaction, the tendency to increase during work up or in the azetropic distillation process
using ethyl acetate distillation and toluene was confirmed (Table 4).
[Table 4] Generation of de-isopropylated impurity
Result (HPLC % ratio)
Process Step 17.6 min 21.4 min (5-bromo-3-cyano-1H-indole, (5-bromo-3-cyano-1 De-isopropylation Impurity) isopropyl-indole) Final IPC (In nd 100 Process Control)
After Work up 0.538 99.462
After Distillation 3.178 96.822
As a result of tracking the de-isopropylated impurity of 5-bromo-3-cyano-1
isopropyl-indole by HPLC analysis, it was not detected in the reaction IPC (In Process
Control), but was observed to increase during the work up and distillation steps. By
using 5-bromo-3-cyano-1-isopropyl-indole obtained as above, the processes of 1-(3
cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester, 1-(3-cyano-1
isopropyl-indol-5-yl)pyrazole-4-carboxylic acid and 1-(3-cyano-1-isopropyl-indol-5
yl)pyrazole-4-carboxylic acid were carried out. Then, the final API (active
pharmaceutical ingredient) was analyzed. As a result, the impurity expected as an
indole dimer was detected, so that the option process was carried out.
Example 2.1.1. Crystallization of 5-bromo-3-cyano-1-isopropyl-indole using i
PrOH
Based on the results obtained by the solubility curve, crystallization of 5-bromo
3-cyano-1-isopropyl-indole using i-PrOH was performed. In the process of
synthesizing 5-bromo-3-cyano-1H-indole using Cs2CO3, 5-bromo-3-cyano-1H-indole is
regenerated by de-isopropylation of 5-bromo-3-cyano-1-isopropyl-indole after layer
separation and participates in 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic
acid ethyl ester reaction to generate indole dimer. In order to search for conditions
capable of inhibiting the generation of indole dimer by removing 5-bromo-3-cyano-1H
indole in advance, after spiking to comprise 0.86%, 1.56% and 3.00% of 5-bromo-3
cyano-1H-indole, they were dissolved under reflux conditions, cooled slowly at room
temperature, kept at 0-5°C for 1 hour, and then filtered. HPLC purity and gross yield of
the obtained crystals were summarized (Table 5).
[Table 5] Residual 5-bromo-3-cyano-1H-indole before and after crystallization of 5
bromo-3-cyano-1-isopropyl-indole using i-PrOH
Result (HPLC %ratio) i-PrOH Time Before After Gross Yield Run (fold) Temp. (h) crystallization crystallization (%) GD40 GD60 GD40 GD60 Example 1.0 Reflux 3 0.86 98.37 0.12 99.68 88 2-1-1 Example 1.0 Reflux 3 1.56 96.83 0.28 99.31 87 2-1-2 Example 1.0 Reflux 3 3.00 94.10 0.59 98.63 81 2-1-3 GD40: 5-Bromo-3-cyano-1H-indole GD60: 5-Bromo-3-cyano-1-isopropyl-indole
As a result of Examples 2-1-1 to 2-1-3, it was confirmed that a small amount of
-bromo-3-cyano-1H-indole, which is de-isopropylated impurity, remained even when crystallization was performed by using 1.0-fold of i-PrOH. When the initial starting material 5-bromo-3-cyano-1H-indole was not sufficiently converted to 5-bromo-3-cyano
1-isopropyl-indole, or the content of 5-bromo-3-cyano-1H-indole was increased by
increasing the de-isopropylated impurity in the work-up process step, it could not be
completely removed even through the crystallization process using 1-fold of i-PrOH was
carried out. Figure 1 is a comparison of HPLC peak areas of residual 5-bromo-3-cyano
1H-indole before and after crystallization of 5-bromo-3-cyano-1-isopropyl-indole.
Example 2.1.2. Crystallization of 5-bromo-3-cyano-1-isopropyl-indole using i
PrOH and anti-solvent (Lab scale)
When crystallization was performed by using i-PrOH, it was confirmed that the
residual 5-bromo-3-cyano-1H-indole was purified, and crystallization conditions were
searched by using anti-solvents to increase the yield. When crystallization was
performed by using i-PrOH, hexane and hetpane, it was confirmed that the residue 5
bromo-3-cyano-1H-indole was effectively removed. There was no significant
difference in the net yield between hexane and heptane (Table 6).
[Table 6] Comparison of residual 5-bromo-3-cyano-1H-indole content before and after
crystallization of 5-bromo-3-cyano-1-isopropyl-indole using anti-solvent
Result (HPLC % ratio) Anti Gross Net i-PrOH Before After Run Solvent Temp. Yield Yield (fold) crystallization crystallization (fold) (%o) (%o) GD40 GD60 GD40 GD60
Example Hexane 1.0 Reflux 0.68 99.32 0.00 99.99 93 90 2-2-1 (2.0)
Example Hexane 1.0 Reflux 1.35 98.65 0.03 99.97 93 91 2-1-2 (2.0)
-1Rx-
Example Hexane 1.0 Reflux 2.59 97.41 0.12 99.88 93 92 2-1-3 (2.0)
Example Heptane Reflux 0.71 99.29 0.02 99.98 94 92 2-1-4 (2.0)
Example Heptane Reflux 1.38 98.62 0.06 99.94 94 92 2-1-5 (2.0)
Example Heptane Reflux 2.54 97.46 0.12 99.88 94 93 2-1-6 (2.0) GD40:5-Bromo-3-cyano-1H-indole GD60:5-Bromo-3-cyano-1-isopropyl-indole
Example 2.1.3. Search for crystallization conditions of 5-bromo-3-cyano-1
isopropyl-indole
Additional tests were performed to determine whether 5-bromo-3-cyano-1H
indole was removed while improving the yield in the crystallization process of 5-bromo
3-cyano-1-isopropyl-indole. After spiking of 0.78% and 2.59%, and crystallization, the
amount of residual 5-bromo-3-cyano-1H-indole was evaluated by HPLC.
When the amount of i-PrOH was reduced, it was confirmed that the yield of 5
bromo-3-cyano-1-isopropyl-indole was improved, but 5-bromo-3-cyano-1H-indole
remained. In view of these results, in order to completely remove the residual 5-bromo
3-cyano-1H-indole, it seemed preferable to proceed with the crystallization under the
condition that 1-fold of i-PrOH is used and 2-fold of heptane is used. However, if
crystallization is carried out in a state in which 5-bromo-3-cyano-1H-indole is present in
an amount of 0.78% or less during the reaction, it was determined that it would be
manageable even if crystallization was performed by using 0.5-fold of i-PrOH (Table 7).
[Table 7] Crystallization condition result of 5-bromo-3-cyano-1-isopropyl-indole through
i-PrOH ratio change
Run i-PrOH Heptane Temp. Result (HPLC % ratio)
- 1 9-
(fold) (fold) Before crystallization After crystallization Gross Yield GD40 GD60 GD40 GD60
Example 1.0 2.0 Reflux 0.71 99.39 0.00 99.99 93 2-3-1
Example - 2.0 Reflux 0.78 99.42 0.68 99.99 95 2-3-2 Example 0.25 2.0 Reflux 0.78 99.42 0.11 99.89 95 2-3-3 Example 0.25 2.0 Reflux 2.59 99.42 0.17 99.83 94 2-3-4
Example 0.50 2.0 Reflux 0.78 97.41 0.04 99.94 94 2-3-5 Example 0.50 2.0 Reflux 2.59 97.41 0.14 99.86 94 2-3-6 GD40: 5-Bromo-3-cyano-1H-indole GD60: 5-Bromo-3-cyano-1-isopropyl-indole
Example 3: Preparation method of 5-bromo-3-cyano-1-isopropyl-indole
Acetone (800 L), 5-bromo-3-cyano-1H-indole (300 kg), KOH (114 kg) and 2
iodopropane (346 kg) were sequentially put into a reactor, and the reaction was carried
out under elevated temperature and reflux conditions. After confirming the completion
of the reaction by HPLC, the reaction mixture was cooled to room temperature. For
extraction and layer separation, EtOAc (1,353 kg) and purified water (1,500 kg) were
additionally added to the reaction mixture, stirred for 1 hour, kept for 1 hour, and the
aqueous layer formed below was discarded. The remaining organic layer was micro
filtrated and concentrated as much as possible by distillation, and residual EtOAc was
checked by GC. After adding 2-propanol (150 L) and heptane (816 kg) to the
concentrated reaction mixture, the temperature was raised to 78°C. When it was
visually confirmed that the reaction mixture was clear, the reaction mixture was
additionally stirred for 30 minutes and then slowly cooled down. Cooling was carried out over about 6 hours, and filtration was performed after keeping at 5-10°C for 1 hour.
The filtered solid was washed with heptane (408 kg) and dried with nitrogen to obtain 5
bromo-3-cyano-1-isopropyl-indole (335.7 kg, 94.0% gross yield).
Example 4: Test results of 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic
acid ethyl ester reaction
Example 4.1. Process study for 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4
carboxylic acid ethyl ester
In the existing preparation process of 1-(3-cyano-1-isopropyl-indol-5
yl)pyrazole-4-carboxylic acid ethyl ester, concentrated crude 5-bromo-3-cyano-1
isopropyl-indole, 1H-pyrazole-4-carboxylic acid ethyl ester, Cul as a catalyst, 1,2
cyclohexanediamine (1,2-CHDA) as a ligand, K2 C3 as a base and toluene as a reaction
solvent were used, and the reaction mixture was stirred for 38-45 hours under reflux
condition, cooled and proceeded to work up using NH 40H and purified water. After
work up, the layer-separated organic layer included excess tar and solid impurities. To
remove these impurities, Na2SO4 and silica gel were added, stirred and then filtered. At
this time, the amount of Na2SO4 and silica gel was used in the same weight ratio as 5
bromo-3-cyano-1-isopropyl-indole, so that a large amount of solid waste was generated
in the filtration process step. The filtrate was transferred to a washed reactor and
concentrated, and after concentration was complete, i-PrOH was added to perform a
crystallization process through temperature increase and cooling to obtain 1-(3-cyano-1
isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester. The average yield of the
existing preparation process was about 56%.
[Reaction Scheme 5] Process of 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4
carboxylic acid ethyl ester
EtO 2C N N CN GD10 EtO 2 C XICN Br HN
N Cul, 1,2-CHDA, K 2CO 3 , Toluene / N Reflux Work up: NH 4 0H, PW GD60 Silica gel, Na 2SO 4 GD65 Filtration Crystallization: i-PrOH
GD1: 1H-pyrazole-4-carboxylic acid ethyl ester GD60: 5-Bromo-3-cyano-1-isopropyl-indole GD65: 1-(3-Cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester
Example 4.1.1. Ligand screening for 1-(3-cyano-1-isopropyl-indol-5
yl)pyrazole-4-carboxylic acid ethyl ester reaction
As in the above process, in the case of 1-(3-cyano--isopropyl-indol-5
yl)pyrazole-4-carboxylic acid ethyl ester, 1,2-CHDA (1,2-cyclohexanediamine, LI) was
used for the C-N coupling reaction. In this case, it was confirmed that the primary amine
ligand is coupled with 5-bromo-3-cyano-1-isopropyl-indole, resulting in excessive 5
bromo-3-cyano-1-isopropyl-indole-ligand impurity. Eventually, the impurity coupled
with the ligand not only affects the yield, but also delays the completion of the reaction
or the reaction is not completed. In order to solve these problems, ligand screening was
performed first. Ligands used for screening were tested by selecting N-N ligands, N-O
ligands and other applicable ligands (Figure 3).
Ligand screening experimental conditions were as follows: 5-bromo-3-cyano-l
isopropyl-indole (1.0 equiv), 1H-pyrazole-4-carboxylic acid ethyl ester (1.0 equiv),
toluene (4 fold, fold = ml/g of 5-bromo-3-cyano-l-isopropyl-indole), Cul (0.2 equiv),
K 2 C3 (2,0 equiv) and ligand (0.4 equiv) were added and stirred at external set
temperature of 125-130C for 24 hours, and the conversion ratio (%) of 5-bromo-3
cyano-1-isopropyl-indole to 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester was used as the evaluation standard (Figure 3).
As can be seen from Figure 3, when the ligand L (1,2-cyclohexanediamine) was
used, the conversion rate was 38.85%, whereas when the ligand L10 (N,N
dimethylethylenediamine, DMEDA) was used, the high conversion rate of 87.28% was
confirmed.
Eventually, if the ligand is changed to L10 at the same reaction time, the reaction
rate is improved and impurity is suppressed, resulting in a higher yield. Except for L2
(1,2-phenanthroline) 0.41% and L7 (JohnPhos) 2.1%, no reaction proceeded at all in the
case of the other ligands.
Example 4.1.2. Base and solvent screening for 1-(3-cyano-1-isopropyl-indol-5
yl)pyrazole-4-carboxylic acid ethyl ester reaction
In Example 4.1.1. it was confirmed the ratio of converting to 1-(3-cyano-1
isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester is increased in the case of
using the Li0 ligand rather than the previously used LI ligand. Next, a screening
experiment for the base was performed (Figure 4).
[Table 8]
Solv. HPLC Conversion Ratio (%) Base : Toluene DMF DMSO K2 C0 3 77.60% 62.20% 64.20% K3 P0 4 81.40% 0 67.70% Na t-butoxide 1.0% 37.9% 3.3 %
Cs2CO3 3.70% 75.80% 5.60%
The experimental conditions of Figure 4 were as follows: 5-bromo-3-cyano-1
isopropyl-indole (1.0 equiv), 1H-pyrazole-4-carboxylic acid ethyl ester (1.0 equiv),
solvent (4 fold, fold = ml/g of 5-bromo-3-cyano-1-isopropyl-indole), Cul (0.2 equiv), base (2.0 equiv) and 1,2-CHDA (0.4 equiv) were added and stirred at the external set temperature of 125-130°C for 24 hours, and the experiment was conducted with the conversion ratio (%) of 5-bromo-3-cyano-1-isopropyl-indole to 1-(3-cyano-1-isopropyl indol-5-yl)pyrazole-4-carboxylic acid ethyl ester as the evaluation standard. First, as the results of the reactions using K2 C0 3 , K3 P0 4 , Na t-butoxide and Cs2CO3 as a base in toluene solvent, the conversion rates of 77.6% and 81.4% were confirmed in K2 C03 and
K 3 P04 . On the other hand, almost no reaction proceeded with Na t-butoxide and Cs2CO3.
When the reaction solvent was changed to DMF, K 2 CO 3 , Na t-butoxide and Cs2CO3
showed good conversion compared to that using toluene, and K 3 P04 did not react at all.
When DMSO was used, it showed a similar tendency to the experiment using toluene,
but the conversion rate was relatively low. In the above experiments, it was determined
that it is preferable to use K 2 C03 as the base and toluene as the solvent in consideration
of the purchase price of the base and solvent, the safety of the preparation process, and
the latter process (work up and distillation).
Example 4.1.3. Catalyst screening for 1-(3-cyano-1-isopropyl-indol-5
yl)pyrazole-4-carboxylic acid ethyl ester reaction
In Example 4.1.1. and Example 4.1.2., it was determined that the reaction rate
and conversion rate are excellent when N,N-dimethylethylenediamine (L10) is used as a
ligand rather than 1,2-cyclohexanediamine (LI), and K 2 C03 and toluene as the base and
reaction solvent are preferable for 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4
carboxylic acid ethyl ester reaction. Because the synthesis of 1-(3-cyano-1-isopropyl
indol-5-yl)pyrazole-4-carboxylic acid ethyl ester is Ullmann reaction in which a copper
source is used as a catalyst for C-N coupling of1H-pyrazole-4-carboxylic acid ethyl ester
and 5-bromo-3-cyano-1-isopropyl-indole, it was necessary to screen various copper
-?A4- catalysts. In addition, it was necessary to study the cross-coupling reaction of the
Buchwald-Hartwig type using a palladium catalyst. The screening experiments for a
total of four catalysts were performed (Figure 5).
Experimental conditions were as follows: 5-bromo-3-cyano-1-isopropyl-indole
(1.0 equiv), 1H-pyrazole-4-carboxylic acid ethyl ester (1.0 equiv), solvent (4 fold, fold =
ml/ g of 5-bromo-3-cyano-1-isopropyl-indole), catalyst (0.2 equiv), K 2 C03 (2.0 equiv)
and 1,2-CHDA (0.4 equiv) were added and stirred at the external set temperature of 125
130°C for 24 hours, and the experiment was conducted with the conversion ratio (%) of
-bromo-3-cyano-1-isopropyl-indole to 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4
carboxylic acid ethyl ester was used as the evaluation standard.
[Table 9]
HPLC Conversion Ratio Cat. Solv. Toluene DMF DMSO Cul 16.10% 0.70% 32.20% CuBr 14.30% 4.40% 8.1 %
CuCl 8.1 % 27.90% 62.30% Pd(OAc)2 0.0 % 0.0 % 0.0 %
In the case of the catalyst screening experiments, a carousel multi reactor was
used. According to the experimental results, although CuCl showed the highest
conversion ratio of 5-bromo-3-cyano-1-isopropyl-indole to 1-(3-cyano-1-isopropyl
indol-5-yl)pyrazole-4-carboxylic acid ethyl ester under DMSO reaction solvent,
debrominated impurity could be detected by HPLC as a side reaction. Although
Pd(OAc)2 was used as the palladium source, the reaction did not proceed at all in the three
reaction solvents. In the case of Cul, debrominated impurity could be detected when
DMSO solvent was used. As a result, when the reaction was carried out by using CuCl
and Cul in DMSO solvent, the conversion rate of 5-bromo-3-cyano--isopropyl-indole to
1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester was high, but it
was confirmed that there was a problem that the production amount of debrominated
impurity increased at the same time. Therefore, it was concluded that DMSO solvent
was not suitable for the reaction. Through the above experiments, it was confirmed that
the conversion rate was higher when Cul was used as a catalyst in the toluene reaction
solvent than when CuBr, CuCl, and Pd(OAc)2 were used. Finally, toluene was selected
as the reaction solvent, and Cul was selected as the catalyst.
Example 5: Test result of removing residual Cu in 1-(3-cyano-1-isopropyl-indol-5
yl)pyrazole-4-carboxylic acid ethyl ester
A new approach was needed to improve the 1-(3-cyano-1-isopropyl-indol-5
yl)pyrazole-4-carboxylic acid ethyl ester work up process. Specifically, a new method
in which the adsorption process is omitted and the layer separation can be effectively
performed was considered. Eventually, there was a need to increase the amount of
purified water used to effectively remove Cu-complex, KBr, K2 C0 3 , excess tar and other
by-products, and a method to effectively remove copper by chelating was required. For
this purpose, work up was performed using citric acid and EDTA
(ethylenediaminetetraacetic acid), which are chelating agents.
Example 5.1. 1-(3-Cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
ethyl ester work up study (II)
Example 5.1.1. Work up study (citric acid)
When performing work up after the reaction in the toluene solvent, the organic
layer and the aqueous layer became a turbid lump, and the layers were not separated well,
so after adding ethyl acetate, work up was carried out. Among the various work up methods to replace NH 40H, when 10% citric acid solution was used, the aqueous layer was clean and the layers were separated well, so it was decided to use 10% citric acid solution for the first work up.
Then, after adding purified water, the pH was lowered to 2-3 using 3N HCl to
clearly break the Cu complex. The next step was the treatment with 5% EDTAdisodium
solution to remove the remaining Cu, and this process was repeated once more. Finally,
purified water was added to wash off any remaining salts (Schematic Diagram 1).
[Schematic Diagram 1] Work up conditions using citric acid
Reaction IPC
1twork up PW, EtOAc, 10% Citric acid
Layer separation (disposal of water layer)
2 nd work up H 20, 3N HCl (pH 2~3)
Layer separation (disposal of water layer)
3 rd work up 5% EDTA disodium
Layer separation (disposal of water layer)
4' work up 5% EDTA disodium
Layer separation (disposal of water layer)
5 t' work up H 20
Layer separation (disposal of water layer)
Evaporation
*Each of the solutions was added by 6-fold.
Example 5.1.2. Work up optimization (10% citric acid + HCl)
When the solution used for the first work up was combined with aq. HCl, it was
attempted to find the optimal ratio showing good layer separation behavior (Table 10).
Based on these results, it was determined that the optimal condition is to use 2-fold of 10%
citric acid aqueous solution and 2-fold of 6N HC aqueous solution, respectively, at the
same time, and the appropriate pH range was 2.75 - 3.5.
[Table 10] Conditions and results of the first work up
) Work up Fold HCl Fold Layer separation Run Fl ~ od p solution appearance 10% NH4 Cl Example 5-1-1 aqueous 3 3N 1 8.12 Cloudy aqueous layer 5-1-1 solution 10% NH4 Cl Example 5-1-2 aqueous 2 3N 2 6.94 Cloudy aqueous layer 5-1-2 solution 10% NH4 Cl Example Very cloudy aqueous 513aqueous 5-1-3 souinlayer 1 3N 3 6.85lae solution 10% citric acid Example 514 aqueous 3 3N 1 7.4 Good layer separation 5-1-4 solution 10% NH4 Cl Example aqueous 3 6N 1 8.1 Cloudy aqueous layer 5-1-5 solution 10% citric acid Example Aqueous layer is full aqueous 3 6N 1 8.5 5-1-6 ofbubbles solution 10% NH4 Cl Example Eap aqueous 4 6N 2 8.1 Bad layer separation 5-1-7 solution Example 10% citric acid 4 6N 2 3.5 Good layer separation, 5-1-8 aqueous Easy to distinguish solution color 10% NH4 Cl Example 8 Aqueous layer is full aqueous 8 - - -ofube 5-1-_9b) of bubbles solution 10% citric acid Good layer separation, Example 5-1-10 aqueous 2 6N 2 2.75 Easy to distinguish solution color
Good layer separation, 10% citric acid Example aqueous 2.5 6N 1.5 4.70 Easy to distinguish 5-1-11 . color, Dark organic layer
Good layer separation, 10% citric acid Example aqueous 2.2 6N 1.8 3.72 Easy to distinguish 5-1-12 color, Dark organic layer a) The reaction was carried out on a 10.0 g scale, b) The reaction was carried out on a 100.0 g scale
Then, a scale-up experiment was performed (Table 11). Ina100.0gscaleusing
a 2 L reactor, when 4-fold of 10% aqueous citric acid solution was added, 2.8-fold of 6N
HCl was added, and when 8-fold of 10% citric acid aqueous solution was added, 2.2-fold
of 6N HCl was added, layer separation was good and color distinguishing was easy.
[Table 11] Conditions and results of the first work up
10% Citric Run Scale acid 6N HCl Layer separation appearance
The presence of floating matter in the Exapl 100.0 g 2 fold 2 fold aqueous layer. The color of the aqueous 5-2-1 layerisnotyetchanged to green. The color of the organic layer becomes very Example dark. Layer separation is good, but there is 100.0 g 2 fold 3 fold 5-2-2 floating matter in the aqueous layer in the next step. Example Good layer separation, Easy to distinguish 20.0Og 4 fold 2.8 fold 5-2-3 color Example 20.0 g 8 fold 2.2 fold Good layer separation, Easy to distinguish
5-2-4 color Example Good layer separation, Easy to distinguish 100.0Og 4 fold 2.8 fold 5-2-5 color Example Good layer separation, Easy to distinguish 100.0Og 4 fold 2.5 fold 5-2-6 color
Conventionally, Cu was removed through a process of filtering after adding silica
gel and Na2SO 4 , but a large amount of solid waste was generated in this process, and a
lot of time was required to treat this solid waste. In order to solve this problem, as a
result of conducting various experiments shown in Example 5, a new work up method
was discovered and the filtration process could be replaced with a work up process
utilizing the chelation principle.
Example 6: Preparation of 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic
acid ethyl ester
Toluene (880 L), 5-bromo-3-cyano-1-isopropyl-indole (220 kg), 1H-pyrazole-4
carboxylic acid ethyl ester (129 kg) and K 2 C03 (231 kg) were added to a reactor, and N 2
purge was performed for about 30 minutes. After adding Cul (32 kg) and DMEDA (30
kg), the internal temperature was raised to 45°C while maintaining the N 2 purge. After
9 hours of reaction under reflux condition, reaction IPC (in process control) was
performed to confirm the completion of the reaction, and the reaction mixture was cooled
to room temperature. The reaction time of 35 hours in the existing process was reduced
to 9 hours. For extraction and layer separation, 10% aqueous citric acid solution (880
L) and EtOAc (794 kg) were sequentially added to the reaction mixture, and then 6 N
HCl (381 kg) was added dropwise to adjust pH = 2-3. After stirring for 30 minutes, the
resulting product was allowed to stand for 1 hour, and the separated aqueous layer was
discarded. After adding 5% EDTA aqueous solution (880 L) to the remaining organic layer, it was stirred for 30 minutes and allowed to stand for 1 hour to proceed with layer separation. The same process was repeated twice in total. Finally, after adding purified water (880 L), the aqueous layer separated by stirring and standing for 30 minutes was discarded. In the above processes, the extraction and layer separation were performed a total of 4 times at about 35°C. The remaining organic layer was distilled as much as possible after microfiltration, and concentrated IPC (in process control) was performed to confirm that EtOAc was removed. After the distillation was completed,
2-propanol (880 L) was added to the reaction mixture, and then the temperature was raised.
When it was confirmed that the reaction mixture was clear, it was cooled slowly to 0
°C for 7-8 hours, kept for about 1 hour and filtered. The filtered solid was washed
with 2-propanol (880 L) and dried using nitrogen and vacuum to obtain 1-(3-cyano-1
isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester (253.5 kg, 94.0% gross yield).
This is about 1.7 times higher than 56% yield of the existing process.
Claims (10)
1. A method for preparing a compound of the following Formula 2, comprising:
i) a step of reacting a compound of Formula 1 and X-R3 with a base comprising
KOH in an organic solvent; and
ii) a step of crystallizing a product obtained in step (i) by using alcohol and an
anti-solvent comprising hydrocarbon having 5 to 8 carbon atoms:
[Formula 1]
R1
XN N \R2
H
[Formula 2]
R1 X
R3
wherein,
X is F, Cl, Br or I;
R1 is hydrogen or CN;
R2 is hydrogen, halogen, C1 -C 7 alkyl, C1 -C 7 alkoxy-Ci-C 7 alkyl or phenyl; and
R3 is hydrogen; CI-C 7 alkyl unsubstituted or substituted by one or more
substituents selected from halogen, C 3 -C 7 cycloalkyl and O-R6; C 3 -C 7 cycloalkyl; or
w
R7 ,wherein R6is C1-C4 alkyl, WisOor S,R7 is hydrogen or C1-C4 alkyl, and n is an integer of 0 to 3.
2. The method according to Claim 1, wherein X-R3 is 2-iodopropane.
3. The method according to Claim 1, wherein the organic solvent is acetone.
4. The method according to Claim 1, wherein the alcohol is one or more selected
from the group consisting of methanol, ethanol, propanol, isopropanol and butanol.
5. The method according to Claim 1, wherein the hydrocarbon having 5 to 8 carbon
atoms is selected from the group consisting of hexane, heptane and a mixture thereof.
6. A method for preparing a compound of the following Formula 4, comprising:
a step of carrying out a C-N coupling reaction of a compound of Formula 2 and
a compound of Formula 3 with a copper catalyst, a base and a ligand comprising N,N
dimethylethylenediamine in an organic solvent:
[Formula 2]
R1
X K\R2
R3
[Formula 3]
R4 N R5 \N
NH
[Formula 4]
R4
R5 I R1 N
R3
wherein,
X is F, Cl, Br or I;
RI is hydrogen or CN;
R2 is hydrogen, halogen, C1 -C 7 alkyl, C1 -C 7 alkoxy-C1-C7 alkyl or phenyl;
R3 is hydrogen; CI-C 7 alkyl unsubstituted or substituted by one or more
substituents selected from halogen, C 3 -C 7 cycloalkyl and O-R6; C 3 -C 7 cycloalkyl; or
W R7 , wherein R6 is CI-C4 alkyl, W is 0 or S, R7 is hydrogen or C1-C4 alkyl,
and n is an integer of 0 to 3;
R4 is hydrogen, halogen or C1 -C 7 alkyl; and
R5 is -C(O)OR8, wherein R8 is hydrogen, C1-C 7 alkyl or C 3 -C 7 cycloalkyl.
7. The method according to Claim 6, wherein the organic solvent is one or more
selected from the group consisting of xylene, toluene, dimethylformamide (DMF) and
dimethyl sulfoxide (DMSO).
8. The method according to Claim 6, wherein the copper catalyst is one or more
selected from the group consisting of Cu, Cu(OAc)2, Cu, Cu20 and CuO.
-1 4-
9. The method according to Claim 6, wherein the base is one or more selected from
the group consisting of potassium carbonate, cesium carbonate, potassium phosphate
tribasic, triethylamine and sodium tert-butoxide.
10. The method according to Claim 6, which further comprises a step of purifying
the compound of Formula 4 by using:
one or more chelating agents selected from the group consisting of EDTA, citric
acid, potassium citrate and sodium citrate; and
one or more ligand reagents selected from the group consisting of ammonium
chloride and aqueous ammonia.
11. The method according to any one of Claims 1 to 5, wherein RI is CN, R2 is
hydrogen, and R3 is isopropyl.
12. The method according to any one of Claims 6 to 10, wherein RI is CN, R2 is
hydrogen, R3 is isopropyl, R4 is hydrogen, and R5 is ethoxycarbonyl (-C(O)OEt).
[Figure 1]
[Figure 1]
GD40 before crystallization GD40 after crystallization
4.00
3.00 3.00
2,00
1.56
1.00 0.86 0,59 0.28 0.12 0,00 X 1 2 3
[Figure 2]
[Figure 2]
OH OH NH2 O OH N N OH L1 NH2 N L2 N L3 L4 L5
IN O O H O N N OH NH P OH L6 L7 L8 L9 L10
- 1/3 - - 1/3 -
[Figure 3]
[Figure 3]
100
80
60
40
20
o L1 L2 L3 L4 L5 L6 L7 L8 L9 L10
[Figure 4]
[Figure 4]
100 100
80 80
60 60
40 40
20 20 DMSO DMSO 0 0 DMF DMF K2CO3 K2CO3 Toluene Toluene K3PO4 K3PO4 Na t- Na t- Cs2CO3 Cs2CO3 butoxide butoxide
2/3 -- - 2/3
[Figure 5]
[Figure 5]
70 70
60 60
50 50
40 40
30 30
20 20
10 10 DMSO DMSO 0 0 DMF DMF CuI Cul Toluene CuBr Toluene CuBr CuCl CuCl Pd(OAc)2 Pd(OAc)2
- 3/3 - - 3/3 -
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0087042 | 2021-07-02 | ||
KR20210087042 | 2021-07-02 | ||
PCT/KR2022/009544 WO2023277658A1 (en) | 2021-07-02 | 2022-07-01 | Method for preparing intermediate for synthesis of xanthine oxidase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2022302841A1 true AU2022302841A1 (en) | 2023-12-21 |
Family
ID=84691985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2022302841A Pending AU2022302841A1 (en) | 2021-07-02 | 2022-07-01 | Method for preparing intermediate for synthesis of xanthine oxidase inhibitor |
Country Status (14)
Country | Link |
---|---|
US (1) | US20240317685A1 (en) |
EP (1) | EP4349809A4 (en) |
JP (1) | JP2024523604A (en) |
KR (1) | KR20230006408A (en) |
CN (1) | CN117561237A (en) |
AR (1) | AR126353A1 (en) |
AU (1) | AU2022302841A1 (en) |
BR (1) | BR112023026062A2 (en) |
CA (1) | CA3221122A1 (en) |
CL (1) | CL2023003910A1 (en) |
CO (1) | CO2024001078A2 (en) |
MX (1) | MX2023014804A (en) |
TW (1) | TWI835186B (en) |
WO (1) | WO2023277658A1 (en) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW225535B (en) * | 1992-11-10 | 1994-06-21 | Hoechst Ag | |
AU2004296191B2 (en) * | 2003-12-04 | 2010-10-28 | Albany Molecular Research, Inc. | Vinca derivatives |
TWI423962B (en) | 2009-10-07 | 2014-01-21 | Lg Life Sciences Ltd | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same |
CN104341396A (en) * | 2013-08-08 | 2015-02-11 | 上海医药集团股份有限公司 | Diaryl hydantoin derivative, as well as preparation method, medicine composition and application thereof |
HUE040489T2 (en) * | 2014-06-03 | 2019-03-28 | Idorsia Pharmaceuticals Ltd | Pyrazole compounds and their use as t-type calcium channel blockers |
CN107286134B (en) * | 2016-04-11 | 2019-04-12 | 上海勋和医药科技有限公司 | 2,4- disubstituted pyrimidines derivatives are as CDK inhibitor and its application |
TW202128677A (en) * | 2019-10-30 | 2021-08-01 | 美商米突倍基公司 | Cd38 inhibitors |
-
2022
- 2022-07-01 AR ARP220101725A patent/AR126353A1/en unknown
- 2022-07-01 CA CA3221122A patent/CA3221122A1/en active Pending
- 2022-07-01 AU AU2022302841A patent/AU2022302841A1/en active Pending
- 2022-07-01 EP EP22833711.9A patent/EP4349809A4/en active Pending
- 2022-07-01 BR BR112023026062A patent/BR112023026062A2/en unknown
- 2022-07-01 US US18/575,630 patent/US20240317685A1/en active Pending
- 2022-07-01 JP JP2023579843A patent/JP2024523604A/en active Pending
- 2022-07-01 KR KR1020220081195A patent/KR20230006408A/en not_active Application Discontinuation
- 2022-07-01 MX MX2023014804A patent/MX2023014804A/en unknown
- 2022-07-01 WO PCT/KR2022/009544 patent/WO2023277658A1/en active Application Filing
- 2022-07-01 CN CN202280044250.8A patent/CN117561237A/en active Pending
- 2022-07-01 TW TW111124828A patent/TWI835186B/en active
-
2023
- 2023-12-27 CL CL2023003910A patent/CL2023003910A1/en unknown
-
2024
- 2024-01-31 CO CONC2024/0001078A patent/CO2024001078A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
CO2024001078A2 (en) | 2024-03-07 |
TW202308994A (en) | 2023-03-01 |
WO2023277658A1 (en) | 2023-01-05 |
BR112023026062A2 (en) | 2024-03-05 |
CA3221122A1 (en) | 2023-01-05 |
MX2023014804A (en) | 2024-01-12 |
CL2023003910A1 (en) | 2024-05-31 |
EP4349809A1 (en) | 2024-04-10 |
EP4349809A4 (en) | 2024-10-09 |
JP2024523604A (en) | 2024-06-28 |
KR20230006408A (en) | 2023-01-10 |
AR126353A1 (en) | 2023-10-11 |
US20240317685A1 (en) | 2024-09-26 |
TWI835186B (en) | 2024-03-11 |
CN117561237A (en) | 2024-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2430092C2 (en) | Method of producing telmisartan | |
RU2480461C2 (en) | Method of producing imatinib and intermediate compounds thereof | |
JP2009527509A5 (en) | ||
CN102686568A (en) | Method for the synthesis of ergothioneine and the like | |
AR023568A1 (en) | A PROCEDURE FOR PREPARING A POLYMORPHIC FORM OF MALEIC ACID SALT DERIVED FROM TIAZOLIDINA-2,4-DIONA | |
AU2022302841A1 (en) | Method for preparing intermediate for synthesis of xanthine oxidase inhibitor | |
JP2010510253A5 (en) | ||
CN112694453B (en) | Preparation method of N-methylated nitrogen-containing aromatic heterocyclic compound | |
TW201209043A (en) | Novel processes | |
CN116768779B (en) | Small molecular compound as immunomodulator, and composition and application thereof | |
CN103443084A (en) | Methods for preparing bendamustine | |
NO317761B1 (en) | Process for the preparation of eprosartan | |
CA2615691A1 (en) | Process for the preparation of crystalline perindopril | |
CN104703967A (en) | Method for purifying fluvoxamine free base and method for preparing highly pure fluvoxamine maleate using same | |
WO2013171643A1 (en) | An improved process for preparation of irbesartan | |
JP2002513021A (en) | Process for producing 1,3-disubstituted-4-oxocyclic ureas | |
KR101485418B1 (en) | A synthetic method of high purity mirtazapine | |
US6582609B2 (en) | Sulfate salt of quinolonecarboxylic acid derivatives and the use thereof | |
JP6126102B2 (en) | Pure S-(−)-9-fluoro-6,7-dihydro-8- (4-hydroxypiperidin-1-yl) -5-methyl-1-oxo-1H, 5H-benzo [i, j] quinolidine -2-carboxylic acid L-arginine salt tetrahydrate and process for producing the same | |
US20100121068A1 (en) | Process for preparing rabeprazole sodium | |
CN111039959B (en) | Method for purifying BCN (BCN-cefcapene pivoxil precursor | |
JP2626710B2 (en) | Method for synthesizing 4-amino-1,2,4- (4H) triazole derivative | |
CN105481831A (en) | New method for preparing dabigatran etexilate intermediate | |
JPH08503930A (en) | Optically active alkylammonium 1- (3-aminophenyl) -ethanesulfonate derivatives, their preparation and use | |
JP2000239279A (en) | Production process for hexahydro-2-oxo-1h-thieno[3,4- d]imidazole-4-pentanoic acid |